Addendum
Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11
Report documents
-
Addendum
Teplizumab (type 1 diabetes mellitus, stage 2, >= 8 years) – Addendum to Project A26-11
Dossier assessment
Indication:
Adult and paediatric patients 8 years of age and older with stage 2 type 1 diabetes mellitus, to delay the onset of stage 3
Result of dossier assessment:
- Unchanged after addendum: For patients with a family history: added benefit not proven (based on the results of the relevant study)
- Unchanged after addendum: For patients without a family history: added benefit not proven (no relevant study)
Additional information
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A26-73
- Commission
- Commission awarded on 23.06.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-73_en
Connected Projects
-
Dossier assessment
Teplizumab (type 1 diabetes mellitus, >= 8 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed